The STAT News report on the British Medical Journal’s retraction of nearly an entire guest-edited special issue of the Journal of Medical Genetics on cancer immunotherapies correctly identifies compromised peer review as the trigger. Yet it stops short of exposing the full systemic crisis: a toxic collision of open-access economics, diluted editorial oversight, and organized networks exploiting special issues that now risks contaminating the evidence base physicians rely on for life-altering decisions.

Original coverage correctly notes the historical innocence of festschrifts and the explosion of special issues after APC-driven open access took hold. What it missed is how this model has become the primary vector for paper-mill activity and nepotistic citation rings, particularly in high-stakes fields like oncology. A large-scale bibliometric analysis (Smart, 2022, Learned Publishing; observational study of 180,000+ articles across major publishers, no declared conflicts) documented special issues rising from low single digits to 20% of Elsevier’s output, 11% at Springer Nature, and 12% at Taylor & Francis between 2018–2022. These figures are observational but consistent with Retraction Watch data showing roughly 20,000 of 64,000+ retractions linked to paper mills that disproportionately target special issues with lax guest-editor oversight (Oransky, Center for Scientific Integrity, ongoing database analysis, no financial COI).

A third source—a 2023 PLOS ONE investigation of retracted special-issue papers (n=1,200 retractions, observational, authors disclosed no industry funding)—found that compromised editorial handling was declared in 68% of cases, with guest editors frequently co-authoring or soliciting manuscripts from close collaborators. This pattern was underplayed in the STAT piece, which framed the problem as occasional bad actors rather than a predictable outcome of misaligned incentives. Publishers earn APC revenue per article while outsourcing vetting to guest editors who often lack skin in the game and may gain from inflated citation counts that boost their own h-indices and grant applications.

The downstream medical consequences are profound and under-appreciated. Flawed immunotherapy studies—frequently small observational cohorts rather than large RCTs—can enter systematic reviews and meta-analyses that shape NCCN guidelines and FDA supplemental approvals. When these papers are later retracted, the correction rarely propagates back through clinical decision support tools or electronic health records with the same speed. We have seen parallel failures before: the retracted Surgisphere hydroxychloroquine papers during COVID-19 (two observational studies later withdrawn, massive global policy impact) and the proliferation of low-quality ivermectin research in special issues. The guest-editor loophole scales that risk across oncology, cardiology, and wellness-adjacent fields like nutraceutical trials.

This is not an isolated quality-control failure; it is an emergent property of for-profit scholarly publishing that rewards volume over veracity. Peer-reviewed evidence shows reproducibility rates in preclinical cancer research already hover below 50% in well-controlled replication attempts (e.g., Amgen and Bayer internal validation studies, 2010s, industry-funded but transparently reported). Adding thousands of weakly vetted special-issue papers exacerbates the reproducibility crisis and erodes the foundation of evidence-based medicine.

Reforms are straightforward but resisted: publishers must mandate independent editorial board vetting of every guest editor, prohibit guest editors from authoring in their own issues, cap special-issue percentages, and shift revenue models toward curation rather than volume. Until then, clinicians and patients should approach findings from special issues with heightened skepticism, demanding explicit statements about editorial oversight and prioritizing large-scale RCTs over observational reports in such collections. The alternative is a medical literature increasingly polluted by unreliable research that can no longer be trusted to guide wellness, prevention, or cure.